TMO vs A

For growth investors, Agilent Technologies, Inc.

(A) is the stronger pick with 6. 7% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Agilent Technologies, Inc. (A) offers the better valuation at 25. 8x trailing P/E (19. 7x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Agilent Technologies, Inc.

(A) is the cheapest at 25. 8x versus Thermo Fisher Scientific Inc. at 26. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 34x versus Thermo Fisher Scientific Inc. 's 9. 02x — a reasonable growth-adjusted valuation.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +2. 1%, compared to -7. 7% for Agilent Technologies, Inc. (A). Over 10 years, the gap is even starker: TMO returned +229. 1% versus A's +202. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 1. 10β versus Agilent Technologies, Inc. 's 1. 23β — meaning A is approximately 12% more volatile than TMO relative to the S&P 500. On balance sheet safety, Agilent Technologies, Inc. (A) carries a lower debt/equity ratio of 50% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agilent Technologies, Inc.

(A) is pulling ahead at 6. 7% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to 3. 2% for Agilent Technologies, Inc.. Over a 3-year CAGR, A leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agilent Technologies, Inc.

(A) is the more profitable company, earning 18. 8% net margin versus 15. 1% for Thermo Fisher Scientific Inc. — meaning it keeps 18. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: A leads at 21. 3% versus 18. 2% for TMO. At the gross margin level — before operating expenses — A leads at 52. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 34x versus Thermo Fisher Scientific Inc. 's 9. 02x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 0x forward P/E versus 19. 7x for Agilent Technologies, Inc. — 0. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for A: 41. 0% to $166. 00.

All stocks in this comparison pay dividends.

Agilent Technologies, Inc. (A) offers the highest yield at 0. 8%, versus 0. 4% for Thermo Fisher Scientific Inc. (TMO).

For long-horizon retirement investors, Agilent Technologies, Inc.

(A) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23), 0. 8% yield, +202. 6% 10Y return). Both have compounded well over 10 years (A: +202. 6%, TMO: +229. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

A pays a dividend while TMO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.